We are live on ! Find out more
BIIB icon

Biogen
BIIB

1,014 hedge funds and large institutions have $59B invested in Biogen in 2017 Q3 according to their latest regulatory filings, with 99 funds opening new positions, 380 increasing their positions, 356 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

65% more funds holding in top 10

Funds holding in top 10: 23 → 38 (+15)

46% more first-time investments, than exits

New positions opened: 99 | Existing positions closed: 68

16% more capital invested

Capital invested by funds: $50.9B → $59B (+$8.14B)

2% more funds holding

Funds holding: 992 → 1,014 (+22)

1.38% more ownership

Funds ownership: 87.77% → 89.15% (+1.4%)

7% more repeat investments, than reductions

Existing positions increased: 380 | Existing positions reduced: 356

22% less call options, than puts

Call options by funds: $974M | Put options by funds: $1.24B

Holders
1,014
Holders Change
+22
Holders Change %
+2.22%
% of All Funds
25.28%
Holding in Top 10
38
Holding in Top 10 Change
+15
Holding in Top 10 Change %
+65.22%
% of All Funds
0.95%
New
99
Increased
380
Reduced
356
Closed
68
Calls
$974M
Puts
$1.24B
Net Calls
-$269M
Net Calls Change
-$87M

Top Buyers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$513M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$310M
3
Ameriprise
Ameriprise
Minnesota
+$178M
4
AQR Capital Management
AQR Capital Management
Connecticut
+$167M
5
Bank of New York Mellon
Bank of New York Mellon
New York
+$133M

Top Sellers

1
BlackRock
BlackRock
New York
-$344M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$206M
3
Renaissance Technologies
Renaissance Technologies
New York
-$190M
4
SIG
Senator Investment Group
New York
-$136M
5
Citadel Advisors
Citadel Advisors
Florida
-$119M
Name Holding Trade Value Shares
Change 		Change in
Stake
JCM
701
Jacobi Capital Management
Pennsylvania
$557K +$25.2K +85 +5%
CLOS
702
Compagnie Lombard Odier SCmA
Switzerland
$544K -$356K -1,202 -41%
PCM
703
Parsons Capital Management
Rhode Island
$541K +$24.9K +84 +5%
CAM
704
Cypress Asset Management
Texas
$534K -$126K -425 -20%
NPC
705
National Planning Corporation
California
$534K +$144K +485 +40%
OPCM
706
Osborne Partners Capital Management
California
$530K – – –
BP
707
Ballentine Partners
Massachusetts
$525K -$5.92K -20 -1%
GI
708
GAMCO Investors
Connecticut
$524K -$22.2K -75 -4%
ITIM
709
Indiana Trust & Investment Management
Indiana
$524K +$888 +3 +0.2%
CB
710
Chemical Bank
Michigan
$520K – – –
GCA
711
Gideon Capital Advisors
New York
$514K +$95.6K +323 +25%
WC
712
Woodstock Corp
Massachusetts
$513K – – –
TRCT
713
Tower Research Capital (TRC)
New York
$513K +$486K +1,641 New
SFM
714
Systematic Financial Management
New Jersey
$501K – – –
IPAM
715
ICICI Prudential Asset Management
India
$500K -$29.6K -100 -6%
AAM
716
Azzad Asset Management
Virginia
$499K +$27.8K +94 +6%
WEC
717
Winslow Evans & Crocker
Massachusetts
$498K -$8.88K -30 -2%
BWM
718
Baystate Wealth Management
Massachusetts
$498K – – –
CCA
719
Checchi Capital Advisers
California
$496K -$21K -71 -4%
GC
720
Garde Capital
Washington
$493K – – –
CIM
721
CIM Investment Management
Pennsylvania
$483K -$523K -1,767 -53%
AGM
722
Alpine Global Management
New York
$483K +$456K +1,541 New
MBT
723
Montecito Bank & Trust
California
$481K +$8.59K +29 +2%
LCM
724
Landscape Capital Management
New Jersey
$481K +$455K +1,535 New
WPA
725
Winning Points Advisors
Florida
$476K – – –
27 28
29
30 31

BIIB Hedge Fund Activity: Q3 2017 in Review

1,014 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Biogen (BIIB) for Q3 2017, worth a combined $59B — up 16% from $50.9B a quarter earlier.

Buyers outnumbered sellers: 99 funds opened new BIIB positions and 68 closed out — a net gain of 31 holders — while 380 added to existing stakes and 356 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $513M. The largest seller was BlackRock, cutting an estimated $344M.

  • 1,014 institutional investors held Biogen (BIIB) as of Q3 2017, up from 992 in Q2 2017.
  • Funds reported $59B of Biogen stock for Q3 2017, up 16% quarter-over-quarter.
  • 99 funds opened new Biogen positions in Q3 2017 and 68 closed out, a net change of +31 holders.
  • The largest Biogen buyer in Q3 2017 was T. Rowe Price Associates, an estimated $513M added.
  • The largest Biogen seller in Q3 2017 was BlackRock, an estimated $344M sold.

Based on aggregated 13F filings for Q3 2017.